reports
Calix Inc: 1 director
A director at Calix Inc sold 25,000 shares at 39.588USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Soleno Therapeutics to Report First Quarter 2025 Financial Results and...
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM ...
Soleno Therapeutics Announces VYKAT(TM) XR Launch
Soleno Therapeutics Announces VYKAT(TM) XR Launch First prescriptions delivered to individuals with PWS REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA)...
Soleno Therapeutics Inc: 1 director
A director at Soleno Therapeutics Inc sold 3,782 shares at 70.110USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
ULTA ULTA BEAUTY INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TITN TITAN MACHINERY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
MCHX MARCHEX INC. CL B
IMMR IMMERSION CORP.
HSC HARSCO CORPORATION
GOGO GOGO INC.
GCO GENESCO INC.
FGEN FIBROGEN INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
LIVE LIVE VENTURES
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
TROX TRONOX HOLDINGS PLC
AEYE AUDIOEYE INC
ZYME ZYMEWORKS INC.
GRWG GROWGENERATION
PRLD PRELUDE THERAPEUTICS
FTHM FATHOM HOLDINGS
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
TOI ONCOLOGY INSTITUTE INC (THE)
HD HOME DEPOT
BTMD INC.
BLIN HAYMAKER ACQUISITION CORP III
BUKS BRIDGELINE DIGITAL INC
MODD BUTLER NATIONAL CORP
MLYS MODULAR MEDICAL INC
WEST MINERALYS THERAPEUTICS INC
SRFM WESTROCK COFFEE COMPANY LLC
GUTS SURF AIR MOBILITY INC.
ADVM FRACTYL HEALTH INC
AFCG ADVERUM BIOTECHNOLOGIES INC.
FG AFC GAMMA
EU INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
- Jonathan Moreland
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PBF PBF ENERGY INC. CLASS A
MCHX MARCHEX INC. CL B
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
LIVE LIVE VENTURES
ZYME ZYMEWORKS INC.
PCB PACIFIC CITY FINANCIAL CORP
PRLD PRELUDE THERAPEUTICS
UAN CVR PARTNERS LP
DRCT DIRECT DIGITAL HLDGS INC
SRFM SURF AIR MOBILITY INC.
ADVM ADVERUM BIOTECHNOLOGIES INC.
SUNS SUNRISE REALTY TRUST
AFCG AFC GAMMA
FG INC.
F AND G ANNUITIES AND LIFE
INC.
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release t...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quart...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year 2024 and Recent Corporate Highlights Regulatory New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatm...
Soleno Therapeutics to Participate in Upcoming February Investor Confe...
Soleno Therapeutics to Participate in Upcoming February Investor Conferences REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: Oppenheimer 35th Annual Healthcare Life Sciences ConferencePresen...
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxfor...
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Up to $200 million financing, includes $50 million upfront REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. “This financing significantly strengthens our financial position, providing additional supp...
- Jonathan Moreland
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
LTRX LANTRONIX INC.
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
EXAS CHART INDUSTRIES INC.
EL EXACT SCIENCES CORPORATION
CROX ESTEE LAUDER COMPANIES INC. CLASS A
CNC CROCS INC.
BRKR CENTENE CORPORATION
APPS BRUKER CORPORATION
AVNW DIGITAL TURBINE
AIN AVIAT NETWORKS
CMCO ALBANY INTERNATIONAL CORP. CLASS A
ENPH COLUMBUS MCKINNON CORPORATION
HTLD ENPHASE ENERGY INC.
SACH HEARTLAND EXPRESS INC.
DMLP SACHEM CAPITAL
HLNE DORCHESTER MINERALS L.P.
ANGI HAMILTON LANE INCORPORATED CLASS A
MBIN ANGI INC. CLASS A
LILA MERCHANTS BANCORP
FF LIBERTY LATIN AMERICA A
MEC FIRST MINING GOLD
NOVA MAYVILLE ENGINEERING
GRWG SUNNOVA ENERGY INTERNATIONAL
PCB GROWGENERATION
CLDX PACIFIC CITY FINANCIAL CORP
FBRX CELLDEX THERAPEUTICS INC.
TFC FORTE BIOSCIENCES INC
ONEW TRUIST FINANCIAL CORP
ARRY ONEWATER MARINE
SSSS ARRAY TECHNOLOGIES
ABCL SUTTER ROCK CAPITAL CORP.
CSU ABCELLERA BIOLOGICS
IMNM CAPITAL SENIOR LIVING
GRNT IMMUNOME
PFBX GRANIT SKOPKE
TRIN PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ZETA TRINITY CAPITAL INC
RWAY ZETA GLOBAL HLDGS CORP
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
CALC NEXGEL INC
DBD CALCIMEDICA INC.
CATX DIEBOLD NIXDORF INCORPORATED
MDRR PERSPECTIVE THERAPEUTICS
PDYN INC.
DC MEDALIST DIVERSIFIED REIT INC.
AGFY SARCOS TECHNOLOGY AND ROBOTICS CORP
ETS DAKOTA GOLD CORP.
AGRIFY CORPORATION
ENTERASYS NETWORKS INC /DE/
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Health...
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’...
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR ...
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome PDUFA target action date extended by three months to March 27, 2025 REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extende...
Marchex Inc: 1 director
A director at Marchex Inc bought 105,571 shares at 1.729USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Jonathan Moreland
MCHX MARCHEX INC. CL B
I3N CHART INDUSTRIES INC.
AGCO AGCO CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
SURG SURGE HOLDINGS
PFBX INC.
SES PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WPC SES AI CORPORATION
W. P. CAREY AND CO. LLC
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
SATS ECHOSTAR CORPORATION CLASS A
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
KVHI KVH INDUSTRIES INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GDOT CHART INDUSTRIES INC.
EXAS GREEN DOT CORPORATION CLASS A
CROX EXACT SCIENCES CORPORATION
CNC CROCS INC.
AGCO CENTENE CORPORATION
AVNW AGCO CORPORATION
ENPH AVIAT NETWORKS
HTLD ENPHASE ENERGY INC.
ZOM HEARTLAND EXPRESS INC.
DMLP ZOMEDICA PHARMACEUTICALS CORP
MAV DORCHESTER MINERALS L.P.
HLNE PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR HAMILTON LANE INCORPORATED CLASS A
MHI SLEEP NUMBER CORPORATION
GNL PIONEER MUNICIPAL HIGH INCOME TRUST
BBDC GALEY & LORD INC.
CLDX BARINGS BDC INC.
ENX CELLDEX THERAPEUTICS INC.
ADV EATON VANCE NEW YORK MUNICIPAL BOND FUND
HPK ADVANTAGE SOLUTIONS INC (A)
MRVI HIGHPEAK ENERGY INC (A)
OPCH MARAVAI LIFESCIENCES HOLDINGS
MODV OPTION CARE HEALTH INC
DCOM MODIVCARE INC
UAN DIME COMMUNITY BANCSHARES
PFBX INC.
OSCR CVR PARTNERS LP
BGS PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WBD OSCAR HEALTH
TCBX B&G FOODS
BIGZ INC.
RXO_w WARNER BROS. DISCOVERY INC.
VANI THIRD COAST BANCSHARES INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
DBD RXO INC
MIO VIVANI MEDICAL INC
WPC WK KELLOGG CO
EVM DIEBOLD NIXDORF INCORPORATED
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
W. P. CAREY AND CO. LLC
EATON VANCE INSD CALIF MUN BD FD
Comfort Systems Usa Inc: 1 director
A director at Comfort Systems Usa Inc sold 15,000 shares at 448.879USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide C...
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, bein...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarte...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi sy...
Soleno Therapeutics to Participate in Upcoming November Investor Confe...
Soleno Therapeutics to Participate in Upcoming November Investor Conferences REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Even...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.